VAXXAS
Vaxxass is a biotechnology company that develops a novel needle-free vaccination technology. The company uses proprietary dry-coating technology that can eliminate or significantly reduce the need for vaccine refrigeration during storage and transportation - easing the resource and logistics burden of maintaining the vaccine "cold chain". Vaxxas was incorporated in 2011 and is based in Brisbane, Australia.
VAXXAS
Social Links:
Industry:
Biotechnology Health Care Medical Device
Founded:
2011-01-01
Address:
Brisbane, Queensland, Australia
Country:
Australia
Website Url:
http://www.vaxxas.com
Total Employee:
51+
Status:
Active
Contact:
61282057379
Total Funding:
102.51 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving SPF Apple Mobile Web Clips Icon Google Font API Google Tag Manager Google Analytics Google Maps Content Delivery Network
Similar Organizations
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Instadiagnostics
Instadiagnostics Inc., is developing a rapid, quantitative, point-of-care (POC) diagnostic platform.
Integral Molecular
Integral Molecular is a research-driven biotechnology company creating innovative technologies and a pipeline of therapeutic antibodies
Osciflex
Osciflex system imitates nature’s process to prevent deadly blood clots.
Pleno
Pleno is a biotechnology company that aims speeding up disease diagnosis and treatment.
Quantitative Radiology Solutions
Quantitative Radiology Solutions offers advanced body-wide quantification of medical images.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Strados Labs
Strados Labs innovates respiratory monitoring using smart biosensors and artificial intelligence.
Current Advisors List
Current Employees Featured
Founder
Investors List
Wellcome Trust
Wellcome Trust investment in Grant - Vaxxas
UniQuest
UniQuest investment in Series C - Vaxxas
OneVentures
OneVentures investment in Series C - Vaxxas
Australian Government
Australian Government investment in Grant - Vaxxas
Australian Government
Australian Government investment in Grant - Vaxxas
Biomedical Advanced Research and Development Authority (BARDA)
Biomedical Advanced Research and Development Authority (BARDA) investment in Grant - Vaxxas
Bill & Melinda Gates Foundation
Bill & Melinda Gates Foundation investment in Grant - Vaxxas
OneVentures
OneVentures investment in Series B - Vaxxas
HealthCare Ventures
HealthCare Ventures investment in Series B - Vaxxas
OneVentures
OneVentures investment in Series A - Vaxxas
Key Employee Changes
| Date | New article |
|---|---|
| 2022-12-01 | Vaxxas Appoints Doug Cubbin as Chief Financial Officer |
| 2022-04-13 | Vaxxas Announces Appointment of Dan Devine as Chief Business Officer and General Counsel |
Official Site Inspections
http://www.vaxxas.com Semrush global rank: 8.9 M Semrush visits lastest month: 454
- Host name: syn112.syd4.hostyourservices.net
- IP address: 43.250.140.38
- Location: Australia
- Latitude: -33.494
- Longitude: 143.2104
- Timezone: Australia/Sydney
More informations about "Vaxxas"
About - Vaxxas
Vaxxas is targeting initial applications in infectious disease and oncology and has forged collaborations with leading global organizations in vaccine commercialization, including Merck/MSD, the United States Biomedical …See details»
Vaxxas - Crunchbase Company Profile & Funding
The company uses proprietary dry-coating technology that can eliminate or significantly reduce the need for vaccine refrigeration during storage and …See details»
Vaxxas - Funding, Financials, Valuation & Investors - Crunchbase
Vaxxas is funded by 10 investors. Biomedical Advanced Research and Development Authority (BARDA) and Wellcome Trust are the most recent investors.See details»
Vaxxas - LinkedIn
Vaxxas is commercializing novel technology that dramatically enhances the performance of existing and next-generation vaccines. The company believes its innovative needle-free technology will help ...See details»
Org Chart Vaxxas - The Official Board
The org chart of Vaxxas contains its 28 main executives including David Hoey, Doug Cubbin and Scott Fry.See details»
Vaxxas - Contacts, Employees, Board Members, Advisors & Alumni …
Vaxxas has 6 current employee profiles, including Chief Financial Officer Doug Cubbin. Vaxxas has 4 board members and advisors, including Paul Kelly.See details»
Vaxxas - Devex
Vaxxas is a venture capital funded technology start-up company developing technology that originated from Professor Mark Kendall's research group at the Australian Institute of …See details»
Vaxxas - The Org
Needle-free vaccination and vaccine delivery solutions that safely and cost effectively amplify vaccine efficacy using Nanopatch technology developed by Vaxxas.See details»
Vaxxas - Overview, News & Similar companies | ZoomInfo.com
Nov 30, 2022 View Vaxxas (www.vaxxas.com) location in Massachusetts, United States , revenue, industry and description. Find related and similar companies as well as employees …See details»
Vaxxas Company Profile - Office Locations, Competitors, Revenue …
Vaxxas $41 m in total funding,. See insights on Vaxxas including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Vaxxas 2025 Company Profile: Valuation, Funding & Investors
Information on valuation, funding, cap tables, investors, and executives for Vaxxas. Use the PitchBook Platform to explore the full profile.See details»
Vaxxas Pty Ltd - VentureRadar
"Vaxxas is focused on enhancing the performance of existing and next generation vaccines with its proprietary Nanopatch™ technology platform. Vaxxas’ Nanopatch contains an ultra-high …See details»
Contact Us - Vaxxas
Contact us to find out more about Vaxxas' novel needle-free technology that dramatically enhances the performance of existing and next-generation vaccines.See details»
Vaxxas - BIO International Convention | BIO
Jun 5, 2023 The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services.See details»
Needle-free vaccine innovator Vaxxas banks $34m from …
Dec 2, 2022 Vaxxas CEO David Hoey is confident in the company’s ability to bring a needle-free vaccine to market. Genevieve de Manio PhotographySee details»
Medtech darling Vaxxas launches $100m raise to fund trials
Oct 22, 2024 For most investors, Vaxxas has been “the one that got away”, with $100 million of the equity raised to date split between just two investors.See details»
Vaxxas announces CEPI partnership to advance needle-free mRNA …
3 days ago Biotech Vaxxas has announced a partnership agreement with the 2017-established Coalition for Epidemic Preparedness Innovations (CEPI), in order to advance the development …See details»
News - Vaxxas
Sep 12, 2024 Vaxxas Awarded US$3.67 million (AU$5.4 million) from global charitable foundation, Wellcome, for Human Clinical Study of Typhoid Vaccination using Needle-Free …See details»
Vaxxas Secures New U.S. Patent For its Needle-Free ... - BioSpace
Mar 19, 2025 BRISBANE, Australia & CAMBRIDGE, Mass.-- (BUSINESS WIRE)-- Vaxxas, a clinical-stage biotechnology company, today announced it has secured a new patent from the …See details»
Provincial funding for children's aid not keeping up with need, …
1 day ago As the Windsor-Essex Children's Aid Society (WECAS) lays off more than two dozen workers due to a $10 million budget shortfall, the ministry responsible for children and social …See details»